Clinical Trial Update: CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study of CID-103, an anti-CD38 antibody, in previously treated relapsed or refractory multiple myeloma has completed. The trial was sponsored by CASI Ph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CID-103 (anti-CD38 antibody)

Snippet

Sponsor: CASI Pharmaceuticals, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED